ProteinLogic

Executive Summary

ProteinLogic has developed ImmiPrint®, a novel diagnostic platform that leverages machine learning to detect non-obvious patterns in soluble immune proteins from blood or other body fluids. By identifying unique signatures of disease presence, stage, and treatment response, ImmiPrint® has the potential to offer earlier and more precise diagnostics across a range of conditions, including cancer, autoimmune disorders, and infectious diseases. The platform's ability to integrate multi-parameter protein data with AI-driven analysis positions it as a promising tool for personalized medicine and companion diagnostics. Despite its innovative approach, ProteinLogic remains a private, early-stage company with limited disclosed funding and no commercial products. The diagnostics market is highly competitive, requiring substantial clinical validation and regulatory approvals to gain adoption. While the technology's potential is significant, the path to commercialization is uncertain. The company's long history since 2004 without major milestones suggests cautious progress. Near-term value creation depends on securing partnerships or advancing clinical studies. Overall, conviction is tempered by the lack of recent catalysts and visibility into financial or operational traction.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with a diagnostic or pharmaceutical company for co-development or licensing40% success
• H1 2027Publication of clinical validation data for ImmiPrint® in a major indication (e.g., cancer or autoimmune disease)30% success
• Q2 2027Receipt of regulatory designation (e.g., CE marking or FDA Breakthrough Device designation) for a specific diagnostic test20% success